Results 121 to 130 of about 693 (177)

BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study. [PDF]

Am J Hematol
Roeker LE, Han Y, Teschemaker A, Mato AR, Thompson MC.   +4 more
europepmc   +1 more source

Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer. [PDF]

Transl Cancer Res
Sun F, Das MS.
europepmc   +1 more source

Analyzing health outcomes measured as bounded counts. [PDF]

J Health Econ
Mullahy J.
europepmc   +1 more source

A comprehensive review and comparison of existing computational methods for protein function prediction. [PDF]

Brief Bioinform
Lin B, Luo X, Liu Y, Jin X.
europepmc   +1 more source

A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study. [PDF]

Future Oncol
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, Van der Heijden MS.   +23 more
europepmc   +1 more source

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma. [PDF]

Blood Cancer J
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa BA, Lesokhin A, Tan CR, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S, Mailankody S, Hashmi H.   +22 more
europepmc   +1 more source

Artificial intelligence for algorithmic trading digital assets: evidence from the Counter-Strike 2 skin market. [PDF]

Front Artif Intell
Guede-Fernández F, Wagle Y, Dias P, Giordano AP, Henriques L, Costa G, Azevedo S.   +6 more
europepmc   +1 more source

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma. [PDF]

Int J Clin Oncol
Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T.   +19 more
europepmc   +1 more source

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. [PDF]

Nat Med
Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD.   +20 more
europepmc   +1 more source